# Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

> **NCT06543966** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 486 (estimated)

## Conditions studied

- Post-operative Nausea and Vomiting (PONV)

## Interventions

- **DRUG:** Aprepitant Injection
- **DRUG:** Aprepitant Injection Placebo

## Key facts

- **NCT ID:** NCT06543966
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-28
- **Primary completion:** 2026-03-28
- **Final completion:** 2026-03-28
- **Target enrollment:** 486 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06543966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06543966, "Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06543966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*